Macobs Technolo. (MACOBSTECH)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 18.39% indicates efficient use of capital
• Sales growth of 15.77% shows demand traction
• Promoter holding of 47.78% provides some alignment with shareholders
• Latest quarter remains profitable with net profit of ₹1 Cr

Concerns

• P/E of 96.39 is extremely expensive despite profit decline of 22.83%
• Piotroski F-Score of 4/9 suggests deteriorating financial health
• No dividend, so investors receive no income while waiting
• Critical balance sheet data (book value, debt/equity, ROE) unavailable for proper analysis

AI Analysis

Let me be honest with you: this is exactly the kind of stock I would walk past, even if it winked at me. Macobs Technolo trades at ₹206.50, a price-to-earnings ratio of 96.39. For that price, you get a company whose profits are shrinking by 22.83% year-over-year. Even if I generously take the latest quarterly net profit of ₹1 Cr and annualise it to ₹4 Cr, that's still roughly a 50-plus multiple. There is no margin of safety here. The business does show some decent capital efficiency — ROCE of 18.39% is respectable — and sales grew 15.77%, but that growth is not flowing to the bottom line. In fact, the Piotroski F-Score of 4 out of 9 tells me the financial health is deteriorating, not improving. I also see no dividend, so I am not being paid to wait. The promoter holding of 47.78% is moderate, but that alone doesn't make a good investment. I have no book value, no debt-equity ratio, no return on equity — the necessary data to judge financial quality are simply missing. In my view, you are being asked to pay a premium price for a small-cap personal care business with declining profits and no visibility into its balance sheet. That's not investing; that's speculation. The stock is near its 52-week low of ₹198.05, but a falling price is not automatically cheap. The PEG ratio of 6.11, even using sales growth, screams overvaluation. I would rather wait on the sidelines and watch how management turns sales growth into real earnings — and how they fund those efforts — before I even consider committing a rupee of my capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer